Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia NCT04007029 CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 Years Jonsson Comprehensive Cancer Center View Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies NCT01175785 Accelerated Pha...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Chron...
Childhood Myelo...
Chronic Phase C...
de Novo Myelody...
Previously Trea...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Relapsing Chron...
Secondary Myelo...
umbilical cord ...
fludarabine pho...
cyclophosphamid...
ex vivo-expande...
total-body irra...
cyclosporine
mycophenolate m...
laboratory biom...
6 Months - 45 Years Nohla Therapeutics, Inc. View Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer NCT00004135 Kidney Cancer
Melanoma (Skin)
filgrastim
therapeutic all...
cyclophosphamid...
fludarabine pho...
peripheral bloo...
18 Years - 65 Years University of Chicago View Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma NCT00091143 Melanoma (Skin)
gp100 antigen
incomplete Freu...
keyhole limpet ...
fludarabine pho...
peripheral bloo...
18 Years - National Cancer Institute (NCI) View Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia NCT00453388 Acute Myeloid L...
de Novo Myelody...
Fanconi Anemia
Previously Trea...
Allogeneic Bone...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Nonmyeloablativ...
Total-Body Irra...
- Fred Hutchinson Cancer Center View Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma NCT00907036 Lymphoma
alemtuzumab
donor lymphocyt...
cyclosporine
fludarabine pho...
melphalan
allogeneic hema...
16 Years - 65 Years National Cancer Institute (NCI) View Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma NCT02280525 Leukemia
Lenalidomide
Rituximab
Fludarabine
Cyclophosphamid...
NK Cells
Cytarabine
18 Years - 80 Years M.D. Anderson Cancer Center View Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant NCT02333162 Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Hemat...
Fludarabine Pho...
Melphalan
Intensity-Modul...
Total Marrow Ir...
Allogeneic Hema...
Peripheral Bloo...
Allogeneic Bone...
Tacrolimus
Mycophenolate M...
Laboratory Biom...
18 Years - 75 Years University of Chicago View Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies NCT01823198 Accelerated Pha...
Acute Erythroid...
Acute Megakaryo...
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
Blast Phase Chr...
Blasts Under 20...
Blasts Under 20...
Chronic Myelomo...
High Risk Myelo...
Myelodysplastic...
Recurrent Chron...
Therapy-Related...
Therapy-Related...
Aldesleukin
Allogeneic CD56...
Allogeneic Hema...
Busulfan
Fludarabine Pho...
Laboratory Biom...
Peripheral Bloo...
Pharmacological...
7 Years - 65 Years M.D. Anderson Cancer Center View Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 Years Fred Hutchinson Cancer Center View Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS NCT01300572 Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center View Natural Killer Cell (CYNK-001) Infusions in Adults With AML NCT04310592 Leukemia
Leukemia, Myelo...
Leukemia, Myelo...
Neoplasms by Hi...
Neoplasms
Immunosuppressi...
Immunologic Fac...
Physiological E...
Alkylating Agen...
Antimetabolites...
Antiviral Agent...
Analgesics, Non...
Anti-infective ...
Analgesics
Peripheral Nerv...
Hematologic Dis...
Hematologic Neo...
Leukemia in Rem...
Relapsed Adult ...
Refractory AML
CYNK-001
18 Years - 80 Years Celularity Incorporated View Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer NCT00020176 Breast Cancer
filgrastim
therapeutic all...
cyclophosphamid...
cyclosporine
fludarabine pho...
peripheral bloo...
18 Years - 70 Years National Cancer Institute (NCI) View Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant NCT01640301 Recurrent Adult...
Recurrent Child...
Secondary Acute...
Therapy-Related...
Donor
Hematopoietic C...
HLA-A*0201 Posi...
Recurrent Acute...
Aldesleukin
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
WT1-Sensitized ...
- Fred Hutchinson Cancer Center View Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies NCT05418088 Recurrent Acute...
Recurrent B Acu...
Recurrent B-Cel...
Recurrent Chron...
Recurrent High ...
Recurrent Indol...
Recurrent Non-H...
Recurrent Trans...
Refractory Acut...
Refractory B Ac...
Refractory B-Ce...
Refractory Chro...
Refractory High...
Refractory Indo...
Refractory Non-...
Refractory Tran...
Anti-CD19/CD20/...
Cyclophosphamid...
Fludarabine Pho...
18 Years - Ohio State University Comprehensive Cancer Center View Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma NCT00006184 Multiple Myelom...
Myeloma Immunog...
Bortezomib
Cyclophosphamid...
Cyclosporine
Doxorubicin hyd...
Etoposide
Fludarabine pho...
Prednisone
Vincristine Sul...
Methotrexate
GMCSF (granuloc...
GCSF (granulocy...
18 Years - 75 Years National Institutes of Health Clinical Center (CC) View Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00119392 B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center View Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia NCT00003145 Accelerated Pha...
Childhood Chron...
Chronic Myeloge...
Chronic Phase o...
Recurrent Disea...
Fludarabine Pho...
Total-Body Irra...
Nonmyeloablativ...
Peripheral Bloo...
Cyclosporine
Mycophenolate M...
Therapeutic All...
Laboratory Biom...
- 74 Years Fred Hutchinson Cancer Center View Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission NCT00070135 Adult Acute Mye...
Acute Myeloid L...
filgrastim
Anti-Thymocyte ...
busulfan
fludarabine pho...
methotrexate
tacrolimus
Allogeneic Hema...
60 Years - 74 Years Alliance for Clinical Trials in Oncology View Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor NCT01598025 Acute Leukemia
Chronic Leukemi...
Myelodysplastic...
Non-Hodgkins Ly...
total-body irra...
thiotepa
fludarabine pho...
melphalan
anti-thymocyte ...
allogeneic hema...
peripheral bloo...
laboratory biom...
- 19 Years Memorial Sloan Kettering Cancer Center View Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia NCT00004862 Leukemia
filgrastim
oblimersen sodi...
cytarabine
fludarabine pho...
16 Years - National Cancer Institute (NCI) View Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia NCT00003619 Chronic Myelopr...
Leukemia
Myelodysplastic...
Thrombocytopeni...
filgrastim
vitamin E
busulfan
cytarabine
etoposide
fludarabine pho...
isotretinoin
topotecan hydro...
bone marrow abl...
peripheral bloo...
19 Years - 90 Years National Cancer Institute (NCI) View CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies NCT02529813 Acute Biphenoty...
Acute Lymphobla...
Blasts 5 Percen...
CD19 Positive
Minimal Residua...
Non-Hodgkin Lym...
Small Lymphocyt...
Stage III Chron...
Stage IV Chroni...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Tisagenlecleuce...
1 Year - 80 Years M.D. Anderson Cancer Center View Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia NCT00357565 Leukemia
Myelodysplastic...
Childhood Acute...
Recurrent Child...
Secondary Acute...
Childhood Acute...
Previously Trea...
Secondary Myelo...
Refractory Anem...
Refractory Anem...
Refractory Anem...
De Novo Myelody...
Childhood Myelo...
filgrastim
busulfan
cyclosporine
fludarabine pho...
melphalan
mycophenolate m...
umbilical cord ...
- 3 Years Masonic Cancer Center, University of Minnesota View Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma NCT00045513 Leukemia
Lymphoma
7-hydroxystauro...
fludarabine pho...
18 Years - University Health Network, Toronto View Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas NCT00043979 Sarcoma
F-18 Fluorodeox...
therapeutic all...
cyclophosphamid...
cyclosporine
doxorubicin hyd...
etoposide
fludarabine pho...
melphalan
prednisone
sirolimus
tacrolimus
vincristine sul...
peripheral bloo...
Filgrastim
Peripheral Bloo...
5 Years - 35 Years National Institutes of Health Clinical Center (CC) View Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer NCT05400122 Colorectal Canc...
Hematologic Mal...
Rectum Cancer
Acute Myeloid L...
Myelodysplastic...
Acute Lymphobla...
Chronic Myeloid...
Chronic Lymphoc...
Hodgkin Lymphom...
Non Hodgkin Lym...
Myeloproliferat...
Plasma Cell Mye...
Vactosertib
Fludarabine Pho...
Cyclophosphamid...
IL-2
Natural Killer ...
18 Years - Case Comprehensive Cancer Center View Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia NCT00276809 Chronic Lymphoc...
alemtuzumab
filgrastim
carmustine
cyclophosphamid...
cytarabine
dexamethasone
etoposide
fludarabine pho...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - 60 Years German CLL Study Group View Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis NCT02528877 Acute Myeloid L...
Primary Myelofi...
Primary Myelofi...
Secondary Acute...
Secondary Myelo...
Allogeneic Bone...
Allogeneic Hema...
Fludarabine Pho...
Laboratory Biom...
Melphalan
Peripheral Bloo...
Pharmacological...
Ruxolitinib Pho...
Sirolimus
Tacrolimus
18 Years - 75 Years City of Hope Medical Center View Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma NCT05470283 Tumor
Metastatic Mela...
Melanoma
OBX-115
Acetazolamide
Cyclophosphamid...
Furosemide
Mesna
Fludarabine Pho...
18 Years - M.D. Anderson Cancer Center View Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases NCT00376519 Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
Secondary Myelo...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
Treg cell infus...
umbilical cord ...
total-body irra...
18 Years - 45 Years Masonic Cancer Center, University of Minnesota View Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) NCT01471444 Disorder Relate...
Leukemia
Transplantation...
Fludarabine
Clofarabine
Busulfan
Thymoglobulin
Stem Cell Infus...
Tacrolimus
Methotrexate
3 Years - 70 Years M.D. Anderson Cancer Center View Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies NCT06383572 Lymphodepleting...
Myeloid Maligna...
Cyclophosphamid...
Fludarabine pho...
Decitabine
18 Years - 75 Years M.D. Anderson Cancer Center View Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma NCT00397800 Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
yttrium Y 90 ib...
50 Years - 75 Years Technical University of Munich View Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD NCT00914940 Graft Versus Ho...
Leukemia
Myelodysplastic...
Fludarabine Pho...
Tacrolimus
Thiotepa
Total-Body Irra...
Magnetic Affini...
Peripheral Bloo...
Allogeneic Hema...
T Cell-Depleted...
14 Years - 55 Years Fred Hutchinson Cancer Center View Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma NCT00062036 Melanoma (Skin)
aldesleukin
filgrastim
incomplete Freu...
interleukin-2 g...
therapeutic tum...
cyclophosphamid...
fludarabine pho...
18 Years - 120 Years National Institutes of Health Clinical Center (CC) View Cellular Therapy With Cord Blood Cells NCT00427557 Multiple Myelom...
Leukemia
Lymphoma
Fludarabine
Melphalan
Umbilical Cord ...
Rituximab
Peripheral Bloo...
- 80 Years M.D. Anderson Cancer Center View Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02057770 Leukemia, Myelo...
busulfan
fludarabine pho...
total-body irra...
Stem cell trans...
cyclophosphamid...
tocilizumab
18 Years - Washington University School of Medicine View Randomized Double Cord Blood Transplant Study NCT00067002 Leukemia, Lymph...
Leukemia, Myelo...
Leukemia, Myelo...
Lymphoma, Non-H...
Expanded alloge...
One Unmanipulat...
Rituxan
Melphalan
Thiotepa
Fludarabine
Cyclophosphamid...
Mesna
Total body irra...
1 Month - 80 Years M.D. Anderson Cancer Center View Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT00024440 Leukemia
filgrastim
oblimersen sodi...
cyclophosphamid...
fludarabine pho...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia NCT00278213 Prolymphocytic ...
alemtuzumab
cyclophosphamid...
fludarabine pho...
mitoxantrone hy...
18 Years - 70 Years German CLL Study Group View Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) NCT00941928 Leukemia
Pediatric Cance...
Epratuzumab
Fludarabine
Cyclophosphamid...
Mesna
Infusion of NK ...
Interleukin-2
- M.D. Anderson Cancer Center View Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT03602898 Acute Lymphobla...
Acute Myeloid L...
Chronic Myelomo...
Chronic Phase C...
Hematopoietic a...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Refractory Acut...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Questionnaire A...
Tacrolimus
Total-Body Irra...
- 65 Years Fred Hutchinson Cancer Center View Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases NCT06013423 Acute Leukemia ...
Acute Lymphobla...
Acute Myeloid L...
Blastic Plasmac...
Hematopoietic a...
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Non-Hodgkin Lym...
Chronic Myeloid...
Biospecimen Col...
Bone Marrow Asp...
Cyclophosphamid...
Cyclosporine
Diagnostic Imag...
Echocardiograph...
Fludarabine Pho...
Multigated Acqu...
Mycophenolate M...
Survey Administ...
Thiotepa
Total-Body Irra...
Umbilical Cord ...
6 Months - 65 Years Fred Hutchinson Cancer Center View Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia NCT01824693 Juvenile Myelom...
Allogeneic Hema...
Busulfan
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Pharmacological...
Tacrolimus
3 Months - 18 Years Children's Oncology Group View Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma NCT00324623 Melanoma (Skin)
Melan-A VLP vac...
adoptive immuno...
therapeutic aut...
cyclophosphamid...
fludarabine pho...
18 Years - 75 Years Centre Hospitalier Universitaire Vaudois View 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01503242 Plasma Cell Mye...
Refractory Plas...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Mycophenolate M...
Peripheral Bloo...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - 65 Years Fred Hutchinson Cancer Center View Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies NCT06383572 Lymphodepleting...
Myeloid Maligna...
Cyclophosphamid...
Fludarabine pho...
Decitabine
18 Years - 75 Years M.D. Anderson Cancer Center View Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission NCT00101140 Adult Acute Ery...
Adult Acute Mon...
Adult Acute Mye...
anti-thymocyte ...
fludarabine pho...
thiotepa
biological ther...
bone marrow abl...
chemotherapy
non-specific im...
peripheral bloo...
radiation thera...
18 Years - 59 Years Eastern Cooperative Oncology Group View Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) NCT02441803 Leukemia
Busulfan
Fludarabine
Clofarabine
Total Body Irra...
Thymoglobulin
Stem Cell Infus...
Cyclophosphamid...
Tacrolimus
Mycophenolate m...
Decitabine
Cytarabine
Idarubicin
18 Years - 60 Years M.D. Anderson Cancer Center View Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT02048813 Anemia
Chronic Lymphoc...
Small Lymphocyt...
Cyclophosphamid...
Fludarabine Pho...
Ibrutinib
Laboratory Biom...
Pharmacogenomic...
Quality-of-Life...
Rituximab
18 Years - 70 Years National Cancer Institute (NCI) View Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia NCT01256398 Acute Lymphobla...
Adult B Acute L...
Alemtuzumab
Allogeneic Hema...
Autologous Hema...
Cyclophosphamid...
Cytarabine
Dasatinib
Daunorubicin Hy...
Dexamethasone
Etoposide Phosp...
Filgrastim
Fludarabine Pho...
In Vitro-Treate...
Laboratory Biom...
Leucovorin Calc...
Melphalan
Mercaptopurine
Methotrexate
Pegfilgrastim
Pharmacological...
Tacrolimus
Vincristine Sul...
18 Years - National Cancer Institute (NCI) View Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS NCT01300572 Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center View Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT03241940 B Acute Lymphob...
CD19 Positive
Minimal Residua...
Philadelphia Ch...
Recurrent Adult...
Recurrent Child...
Refractory Acut...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Questionnaire A...
1 Year - 30 Years Stanford University View Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia NCT00002838 Leukemia
Filgrastim (G-C...
Cyclophosphamid...
Fludarabine Pho...
Peripheral Bloo...
- 65 Years M.D. Anderson Cancer Center View A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors NCT05672459 Solid Tumor
Single Injectio...
Fludarabine pho...
Cyclophosphamid...
leukapheresis
18 Years - M.D. Anderson Cancer Center View Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention NCT02423915 Leukemia
Lymphoma
Rituximab
Fludarabine
Cyclophosphamid...
Total Body Radi...
Fucosylated Reg...
Cord Blood Infu...
Mycophenolate m...
Sirolimus
Bone Marrow Asp...
G-CSF
Non-Fucosylated...
18 Years - 80 Years M.D. Anderson Cancer Center View A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia NCT05761171 Recurrent Acute...
Recurrent Acute...
Recurrent Acute...
Recurrent Acute...
Recurrent Acute...
Recurrent Mixed...
Refractory Acut...
Refractory Acut...
Refractory Acut...
Refractory Acut...
Refractory Acut...
Refractory Mixe...
Biospecimen Col...
Bone Marrow Asp...
Calaspargase Pe...
Cytarabine
Echocardiograph...
Fludarabine Pho...
Hydrocortisone ...
Lumbar Puncture
Methotrexate
Multigated Acqu...
Prednisolone
Prednisone
Revumenib
Vincristine Sul...
1 Month - 6 Years Children's Oncology Group View Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia NCT00612612 B-cell Chronic ...
Leukemia
Prolymphocytic ...
Refractory Chro...
Stage I Chronic...
Stage II Chroni...
Stage III Chron...
Stage IV Chroni...
obatoclax mesyl...
fludarabine pho...
rituximab
laboratory biom...
18 Years - National Cancer Institute (NCI) View Safety and Efficacy of Campath in Nonmyeloablative Transplantation NCT00038844 Lymphoma
Leukemia
Campath-1 H (Al...
Fludarabine
Cyclophosphamid...
Rituximab
- 70 Years M.D. Anderson Cancer Center View Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer NCT00027820 Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
Childhood Renal...
Chronic Myelomo...
Clear Cell Rena...
de Novo Myelody...
Metastatic Rena...
Previously Trea...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Refractory Chil...
Refractory Chro...
Renal Medullary...
Type 1 Papillar...
Type 2 Papillar...
Untreated Adult...
Untreated Adult...
Untreated Child...
Fludarabine Pho...
Total-Body Irra...
Peripheral Bloo...
Nonmyeloablativ...
Cyclosporine
Mycophenolate M...
- Fred Hutchinson Cancer Center View ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma NCT04579523 Plasma Cell Mye...
Recurrent Plasm...
Refractory Plas...
Allogeneic Hema...
Astatine At 211...
Cyclophosphamid...
Fludarabine Pho...
Total-Body Irra...
18 Years - 70 Years Fred Hutchinson Cancer Center View Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) NCT01471444 Disorder Relate...
Leukemia
Transplantation...
Fludarabine
Clofarabine
Busulfan
Thymoglobulin
Stem Cell Infus...
Tacrolimus
Methotrexate
3 Years - 70 Years M.D. Anderson Cancer Center View Cellular Therapy With Cord Blood Cells NCT00427557 Multiple Myelom...
Leukemia
Lymphoma
Fludarabine
Melphalan
Umbilical Cord ...
Rituximab
Peripheral Bloo...
- 80 Years M.D. Anderson Cancer Center View Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma NCT00006233 Melanoma (Skin)
therapeutic all...
cyclosporine
fludarabine pho...
mycophenolate m...
peripheral bloo...
radiation thera...
18 Years - 64 Years Fred Hutchinson Cancer Center View Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support NCT00506857 Hematologic Mal...
Busulfan
Fludarabine
- 75 Years M.D. Anderson Cancer Center View Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia NCT00513747 Leukemia
rituximab
fludarabine pho...
18 Years - Alliance for Clinical Trials in Oncology View Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission NCT00305708 Congenital Ameg...
Diamond-blackfa...
Fanconi Anemia
Leukemia
Severe Congenit...
Thrombocytopeni...
anti-thymocyte ...
busulfan
fludarabine pho...
allogeneic bone...
peripheral bloo...
umbilical cord ...
radiation thera...
- 17 Years University of California, San Francisco View Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant NCT01251575 Adult Acute Lym...
Adult Acute Mye...
Adult Diffuse L...
Adult Myelodysp...
Adult Non-Hodgk...
Aggressive Non-...
Childhood Acute...
Childhood Acute...
Childhood Diffu...
Childhood Myelo...
Childhood Non-H...
Chronic Lymphoc...
Chronic Lymphoc...
Chronic Phase C...
Hematopoietic a...
Mantle Cell Lym...
Plasma Cell Mye...
Prolymphocytic ...
Recurrent Chron...
Refractory Chro...
T-Cell Prolymph...
Waldenstrom Mac...
Recurrent Diffu...
Recurrent Hodgk...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Sirolimus
Total-Body Irra...
- Fred Hutchinson Cancer Center View Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01707004 Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Secondary Acute...
decitabine
fludarabine pho...
busulfan
cyclophosphamid...
tacrolimus
mycophenolate m...
filgrastim
total-body irra...
allogeneic bone...
laboratory biom...
18 Years - 75 Years University of Wisconsin, Madison View Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant NCT02333162 Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Hemat...
Fludarabine Pho...
Melphalan
Intensity-Modul...
Total Marrow Ir...
Allogeneic Hema...
Peripheral Bloo...
Allogeneic Bone...
Tacrolimus
Mycophenolate M...
Laboratory Biom...
18 Years - 75 Years University of Chicago View Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML NCT00871689 Leukemia
aldesleukin
cyclophosphamid...
fludarabine pho...
umbilical cord ...
total-body irra...
- 45 Years Masonic Cancer Center, University of Minnesota View Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide NCT00800839 Hematologic Dis...
Leukemia
Lymphoma
Myeloma
Busulfan
Fludarabine
Cyclophosphamid...
6 Months - 75 Years M.D. Anderson Cancer Center View Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT03813147 Acute Myeloid L...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Azacitidine
Cytarabine
Fludarabine Pho...
Methotrexate
Pevonedistat
Therapeutic Hyd...
1 Month - 21 Years National Cancer Institute (NCI) View Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD NCT00914940 Graft Versus Ho...
Leukemia
Myelodysplastic...
Fludarabine Pho...
Tacrolimus
Thiotepa
Total-Body Irra...
Magnetic Affini...
Peripheral Bloo...
Allogeneic Hema...
T Cell-Depleted...
14 Years - 55 Years Fred Hutchinson Cancer Center View Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma NCT00608374 Lymphoma
chlorambucil
fludarabine pho...
quality-of-life...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia NCT00003729 Leukemia
cytarabine
fludarabine pho...
idarubicin
- 17 Years European Organisation for Research and Treatment of Cancer - EORTC View TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma NCT02652468 Lymphoma
Fludarabine Pho...
Mesna
Cyclophosphamid...
Total nodal irr...
T Cell-Depleted...
Allogeneic Hema...
Peripheral Bloo...
Mycophenolate M...
Tacrolimus
Rituximab
18 Years - 75 Years University of Wisconsin, Madison View Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) NCT01019317 Leukemia
AML
MDS
CML
Cytarabine
Fludarabine
12 Years - M.D. Anderson Cancer Center View Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer NCT00006261 Breast Cancer
therapeutic all...
cyclophosphamid...
docetaxel
doxorubicin hyd...
fludarabine pho...
peripheral bloo...
18 Years - 60 Years Case Comprehensive Cancer Center View